治疗尿路上皮癌的新型免疫治疗方法。
Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.
作者信息
Muthigi Akhil, George Arvin K, Brancato Sam J, Agarwal Piyush K
机构信息
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10- Hatfield CRC, Room 2-5952, Bethesda, MD 20892, USA.
出版信息
Ther Adv Urol. 2016 Jun;8(3):203-14. doi: 10.1177/1756287216628784. Epub 2016 Feb 9.
Abstract
Immunotherapy has long played a role in urothelial cancers with the use of bacille Calmette Guérin (BCG) being a mainstay in the treatment of nonmuscle invasive bladder cancer. Novel therapeutic approaches have not significantly impacted mortality in this population and so a renaissance in immunotherapy has resulted. This includes recombinant BCG, oncolytic viruses, monoclonal antibodies, vaccines, and adoptive T-cell therapy. Herein, we provide a review of the current state of the art and future therapies regarding immunotherapeutic strategies for urothelial carcinoma.
摘要
长期以来，免疫疗法在尿路上皮癌治疗中发挥着作用，其中卡介苗（BCG）是治疗非肌层浸润性膀胱癌的主要手段。新型治疗方法对该人群的死亡率并未产生显著影响，因此免疫疗法得以复兴。这包括重组卡介苗、溶瘤病毒、单克隆抗体、疫苗和过继性T细胞疗法。在此，我们对尿路上皮癌免疫治疗策略的当前技术水平和未来疗法进行综述。
相似文献
1
Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.
Ther Adv Urol. 2016 Jun;8(3):203-14. doi: 10.1177/1756287216628784. Epub 2016 Feb 9.
2
Nonmuscle invasive bladder cancer: a primer on immunotherapy.
Cancer Biol Med. 2016 Jun;13(2):194-205. doi: 10.20892/j.issn.2095-3941.2016.0020.
3
Immunotherapy for the Treatment of Urothelial Carcinoma.
J Urol. 2017 Jan;197(1):14-22. doi: 10.1016/j.juro.2016.02.3005. Epub 2016 Jul 25.
4
Evolving immunotherapy strategies in urothelial cancer.
Am Soc Clin Oncol Educ Book. 2015:e284-90. doi: 10.14694/EdBook_AM.2015.35.e284.
5
Intravesical immunotherapy in nonmuscle invasive bladder cancer.
Indian J Urol. 2015 Oct-Dec;31(4):304-11. doi: 10.4103/0970-1591.166452.
6
Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
Actas Urol Esp. 2016 Jul-Aug;40(6):370-7. doi: 10.1016/j.acuro.2015.12.009. Epub 2016 Feb 24.
7
Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments.
Curr Opin Oncol. 2019 May;31(3):183-187. doi: 10.1097/CCO.0000000000000533.
8
[Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
Urologe A. 2020 Jul;59(7):810-816. doi: 10.1007/s00120-020-01237-2.
9
BCG: A throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy.
Can J Urol. 2017 Jun;24(3):8788-8793.
10
Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.
Expert Rev Anticancer Ther. 2015 Jan;15(1):85-93. doi: 10.1586/14737140.2015.961430. Epub 2014 Sep 18.
引用本文的文献
1
From plague to the promise: The journey of Bacille Calmette-Guérin.
Bladder (San Franc). 2024 Dec 30;11(4):e21200022. doi: 10.14440/bladder.2024.0035. eCollection 2024.
2
BCG as a Vector for Novel Recombinant Vaccines against Infectious Diseases and Cancers.
Vaccines (Basel). 2020 Dec 4;8(4):736. doi: 10.3390/vaccines8040736.
3
Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.
Virchows Arch. 2020 Apr;476(4):535-542. doi: 10.1007/s00428-019-02661-2. Epub 2019 Sep 2.
4
New therapies in nonmuscle invasive bladder cancer treatment.
Indian J Urol. 2018 Jan-Mar;34(1):11-19. doi: 10.4103/iju.IJU_296_17.
5
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.
Nat Rev Urol. 2018 Feb;15(2):92-111. doi: 10.1038/nrurol.2017.179. Epub 2017 Nov 14.
6
Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells.
Saudi Med J. 2017 Apr;38(4):359-365. doi: 10.15537/smj.2017.4.17061.
本文引用的文献
1
Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street.
J Immunol. 2015 Aug 1;195(3):755-61. doi: 10.4049/jimmunol.1500751.
2
Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond.
Expert Rev Anticancer Ther. 2015 May;15(5):509-23. doi: 10.1586/14737140.2015.1015419. Epub 2015 Apr 16.
3
Adoptive cell transfer as personalized immunotherapy for human cancer.
Science. 2015 Apr 3;348(6230):62-8. doi: 10.1126/science.aaa4967.
4
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29.
5
Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Eur Urol. 2015 Oct;68(4):611-7. doi: 10.1016/j.eururo.2015.02.022. Epub 2015 Mar 5.
6
Cancer immunology - development of novel anti-cancer therapies.
Swiss Med Wkly. 2015 Feb 4;145:w14066. doi: 10.4414/smw.2015.14066. eCollection 2015.
7
Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.
Mol Immunol. 2015 Oct;67(2 Pt A):46-57. doi: 10.1016/j.molimm.2014.12.009. Epub 2015 Jan 13.
8
Cancer statistics, 2015.
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
9
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904.
10
Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis.
Int Urol Nephrol. 2015 Jan;47(1):87-94. doi: 10.1007/s11255-014-0866-z. Epub 2014 Nov 11.
Zotero 插件